HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

Abstract
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.
AuthorsQiuying Selina Liu, Nour Ali Ass'ad, Cecilia Arana Yi
JournalClinical case reports (Clin Case Rep) Vol. 9 Issue 5 Pg. e03164 (May 2021) ISSN: 2050-0904 [Print] England
PMID34094551 (Publication Type: Case Reports)
Copyright© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: